Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

ClinicalTrials.gov ID: NCT06993610

Public ClinicalTrials.gov record NCT06993610. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

Study identification

NCT ID
NCT06993610
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Zura Bio Inc
Industry
Enrollment
225 participants

Conditions and interventions

Interventions

Biological · Other

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 15, 2025
Primary completion
Oct 31, 2026
Completion
Mar 31, 2027
Last update posted
Jun 29, 2026

2025 – 2027

United States locations

U.S. sites
34
U.S. states
18
U.S. cities
33
Facility City State ZIP Site status
Medical Dermatology Specialists (Phoenix) Phoenix Arizona 85006
First OC Dermatology Research, Inc. Irvine California 92614
Wallace Medical Group, Inc. Los Angeles California 90056
Northridge Clinical Trials Northridge California 91325
NorCal Clinical Research Rocklin California 95765
Florida Academic Dermatology Center Coral Gables Florida 33134
Skin Care Research, LLC Hollywood Florida 33021
Georgia Skin & Cancer Clinic Savannah Georgia 31419
Indiana University School of Medicine Indianapolis Indiana 46202
The Indiana Clinical Trials Center Plainfield Indiana 46168
Equity Medical LLC (Kentucky) Bowling Green Kentucky 42104
DS Research of Kentucky, LLC Louisville Kentucky 40241
DelRicht LLC Baton Rouge Louisiana 70809
Clinical Trials Management, LLC Metairie Louisiana 70006
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
MediSearch Clinical Trials Saint Joseph Missouri 64506
Skin Cancer and Dermatology Institute Reno Nevada 89509
Equity Medical New York New York 10023
OptiSkin Medical New York New York 10128
Red River Research Partners Fargo North Dakota 58103
Optima Research Boardman Ohio 44512
ClinOhio Research Services Columbus Ohio 43213
Apex Clinical Research Center Mayfield Heights Ohio 44124
Best Skin Research LLC Camp Hill Pennsylvania 17011
Palmetto Clinical Trial Services Anderson South Carolina 29625
DelRicht Research Mt. Pleasant South Carolina 29464
International Clinical Research - Tennessee LLC Murfreesboro Tennessee 37130
Dermatology Treatment and Research Center Dallas Texas 75230
BRCR Global Texas Katy Texas 77450
DelRicht Research Prosper Texas 75078
Progressive Clinical Research San Antonio Texas 78213
Frontier Dermatology Mill Creek Washington 98012
University of Washington Medical Center Seattle Washington 98164
Dermatology Specialists of Spokane Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06993610, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06993610 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →